{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["de Brabander J"],"funding":["Horizon 2020 Framework Programme"],"pagination":["145"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9163524"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["Dexamethasone improves clinical outcomes in COVID-19 patients requiring supplementary oxygen. We investigated possible mechanisms of action by comparing sixteen plasma host response biomarkers in general ward patients before and after implementation of dexamethasone as standard of care. 48 patients without and 126 patients with dexamethasone treatment were sampled within 48 h of admission. Endothelial cell and coagulation activation biomarkers were comparable. Dexamethasone treatment was associated with lower plasma interleukin (IL)-6 and IL-1 receptor antagonist levels, whilst other inflammation parameters were not affected. These data argue against modification of vascular-procoagulant responses as an early mechanism of action of dexamethasone in COVID-19."],"journal":["Respiratory research"],"pubmed_title":["Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward."],"pmcid":["PMC9163524"],"funding_grant_id":["847786"],"pubmed_authors":["Raasveld J","Prins JM","Vlaar APJ","van der Poll T","Nossent EJ","Peters E","Sigalof K","Wouters D","van Baarle FEHP","Dongelmans DA","Dujardin RWG","Schuurman AR","van der Valk M","Michels EHA","Hagens LA","Koning R","Schultz MJ","Grobusch MP","Zwinderman K","Smit MR","Algera AG","de Bree GJ","Horn J","de Bruin S","Douma RA","Smeele P","Buis DTP","Bonta PI","van Linge CCA","Hemke R","Brouwer MC","van de Beek D","Vught LA","Geerlings SE","Preckel B","de Rotte MCFJ","van Engelen TSR","Schuurmans J","Tuinman PR","Geijtenbeek TBH","Elbers PE","Dijkstra M","Paulus F","Goorhuis B","Hamann J","Hermans SM","Cloherty APM","Bomers M","Hafkamp FMJ","van Agtmael MA","Schrauwen FAP","Bulle EB","Thoral P","Bax DJC","Bogaard HJ","Slim MA","Botta M","van Mourik N","Wiersinga WJ","van Vugt M","Chouchane O","Reijnders TDY","Hovius JW","Heunks LMA","de Brabander J","Stijnis CS","de Vries H","Veelo DP","Tsonas AM","Volleman C","Girbes ARJ","de Jong MD","Bos LDJ","Fleuren LM","Bugiani M","Schinkel M","Harris VC","Amsterdam UMC COVID-19 biobank study group","Lim EHT","Nellen J","Hollmann MW","Appelman B","Beudel M","Pina-Fuentes DAI","Teunissen CE"],"additional_accession":[]},"is_claimable":false,"name":"Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward.","description":"Dexamethasone improves clinical outcomes in COVID-19 patients requiring supplementary oxygen. We investigated possible mechanisms of action by comparing sixteen plasma host response biomarkers in general ward patients before and after implementation of dexamethasone as standard of care. 48 patients without and 126 patients with dexamethasone treatment were sampled within 48 h of admission. Endothelial cell and coagulation activation biomarkers were comparable. Dexamethasone treatment was associated with lower plasma interleukin (IL)-6 and IL-1 receptor antagonist levels, whilst other inflammation parameters were not affected. These data argue against modification of vascular-procoagulant responses as an early mechanism of action of dexamethasone in COVID-19.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-07-14T21:33:58.402Z","creation":"2024-11-13T01:38:53.471Z"},"accession":"S-EPMC9163524","cross_references":{"pubmed":["35659223"],"doi":["10.1186/s12931-022-02060-3"]}}